RxDoctor Payments Data

Rachel Darken, MD

Neurology · Saint Louis, MONPI 1134248891

Payments from drug & device makers

$1,522in general payments, 2019–2025

Across 59 payments — averaging $25.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$563
  • Jazz Pharmaceuticals Inc.$383
  • Lundbeck LLC$295
  • Pfizer$139
  • Inspire Medical Systems, Inc.$83
  • Amgen$35
  • plus $25 from 1 others

What the payments were for

  • Food & beverage$1,522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)36$563
Jazz Pharmaceuticals Inc.3$383
Lundbeck LLC5$295
Pfizer10$139
Inspire Medical Systems, Inc.3$83
Amgen1$35
Lilly USA, LLC1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,522 in reported general payments places this provider in the 50th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$298,102
Medicare patients
266
Services billed
35,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl23$248,106
LumryzSodium Oxybate12$209,678
UbrelvyUbrogepant68$74,318
Nurtec OdtRimegepant Sulfate61$71,498
Emgality PenGalcanezumab-Gnlm69$63,465
Aimovig AutoinjectorErenumab-Aooe55$52,189
Ajovy AutoinjectorFremanezumab-Vfrm35$33,365
Emgality SyringeGalcanezumab-Gnlm13$22,078
Sumatriptan Succinate70$7,071
Modafinil21$6,593
Adderall XrDextroamphetamine/Amphetamine12$4,657
Pregabalin87$3,310
Venlafaxine Hcl ErVenlafaxine Hcl53$3,253
Ropinirole ErRopinirole Hcl11$1,790
Gabapentin84$1,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$563$74,31868 claims
PfizerNurtec Odt$139$71,49861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 381 neurology providers in Missouri.

Other neurology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →